Trials / Completed
CompletedNCT02176239
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- BriovaRx Infusion Services · Industry
- Sex
- All
- Age
- 15 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the utility of measuring outcomes in 5% treatment naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) patients using infusion nurse and patient measured physical, quality of life (QOL), respiratory, and disability assessments using CareExchange in the home setting.
Conditions
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2019-08-01
- Completion
- 2019-08-01
- First posted
- 2014-06-27
- Last updated
- 2019-08-07
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02176239. Inclusion in this directory is not an endorsement.